Programmed cell death protein blockade with pembrolizumab for classical
Hodgkin lymphoma after autologous stem cell transplantation in an
adolescent patient
- Irtiza Sheikh
, - David McCall,
- Cesar Nunez,
- Michael Roth,
- Branko Cuglievan
Michael Roth
University of Texas MD Anderson Cancer Center Children's Cancer Hospital
Author ProfileBranko Cuglievan
University of Texas MD Anderson Cancer Center
Author Profile30 Aug 2021Submitted to Pediatric Blood & Cancer 30 Aug 2021Submission Checks Completed
30 Aug 2021Assigned to Editor
31 Aug 2021Reviewer(s) Assigned
03 Sep 2021Review(s) Completed, Editorial Evaluation Pending
05 Sep 2021Editorial Decision: Revise Minor
17 Sep 20211st Revision Received
17 Sep 2021Submission Checks Completed
17 Sep 2021Assigned to Editor
17 Sep 2021Review(s) Completed, Editorial Evaluation Pending
17 Sep 2021Editorial Decision: Accept
